🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,911 results for “Pharma” Clear

  1. Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine

    Taiho Pharma Netherlands B.V.

    Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 3 small molecule active

    1 trial

  2. Azelastine hydrochloride and Fluticasone propionate

    Teva Pharma GmbH

    Seasonal Allergic Rhinitis

    phase 3 small molecule active

    1 trial

  3. Azetukalner

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    3 trials

  4. Azetukalner

    Xenon Pharmaceuticals

    Bipolar Disorder

    phase 3 small molecule active

    1 trial

  5. Azetukalner

    Xenon Pharmaceuticals

    Bipolar Depression

    phase 3 small molecule active

    1 trial

  6. Azilsartan

    Takeda Pharmaceuticals International AG

    Pediatric Hypertension

    phase 3 small molecule completed

    2 trials

  7. Azilsartan Medoxomil

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    7 trials

  8. Azilsartan Medoxomil and amlodipine

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  9. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Safety

    phase 3 small molecule completed

    1 trial

  10. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    2 trials

  11. Azilsartan medoxomil and chlorthalidone

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    4 trials

  12. Azilsartan medoxomil and olmesartan

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  13. Azilsartan medoxomil with or without add-on chlorthalidone

    Takeda Pharmaceuticals International AG

    Hypertension

    phase 3 small molecule completed

    1 trial

  14. Azilsartan medoxomil/placebo

    Takeda Pharmaceuticals International AG

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  15. BAX 326

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  16. BAX 326 (Recombinant factor IX)

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  17. BAX326

    Takeda Pharmaceuticals International AG

    Hemophilia B

    phase 3 mab completed

    1 trial

  18. BAX855

    Takeda Pharmaceuticals International AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  19. BAY 1841788, TRIPTORELIN

    Cancer Prevention Pharma (Ireland) Limited

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  20. BDP

    Teva Pharma GmbH

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  21. BDP HFA

    Teva Pharma GmbH

    Seasonal Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  22. BDP Nasal Aerosol

    Teva Pharma GmbH

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  23. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, BEZAFIBRATE LP 400 mg, BEFIZAL 200 mg, comprimé pelliculé, Placebo BEZAFIBRATE 200 mg

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  24. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources